Resveratrol for the Prevention of Bone Loss in Postmenopausal Women

Last updated: July 21, 2025
Sponsor: University of Delaware
Overall Status: Active - Not Recruiting

Phase

N/A

Condition

Post-menopausal Osteopenia

Treatment

Resveratrol

Placebo

Clinical Study ID

NCT06250283
2043372
U54GM104941
  • Female
  • Accepts Healthy Volunteers

Study Summary

The purpose of this study is to examine whether daily supplementation of resveratrol would improve bone health in postmenopausal women.

Eligibility Criteria

Inclusion

Inclusion Criteria:

1 to 10 years postmenopausal women with low bone mass

Exclusion

Exclusion Criteria:

  • Osteoporosis

  • Taking blood thinners, endocrine, or neuroactive drugs

  • Hormone therapy

  • Diagnosed: Metabolic bone disease, renal disease, kidney stones, cancer,cardiovascular disease, diabetes mellitus, respiratory disease, gastrointestinaldisease, liver disease

  • Severe menopausal symptoms, serious mood alterations, sleep disturbances

  • Abnormal uterine bleeding, endometriosis, pelvic inflammatory disease

  • Endometrial polyps, and significant uterine fibroids

  • Smokers (≥ 20 cigarettes per day)

  • BMI <20 and > 30 kg/m2

  • Intolerance or allergic reaction to resveratrol, microcrystalline cellulose, grapes,red wine, or blueberries

Study Design

Total Participants: 68
Treatment Group(s): 2
Primary Treatment: Resveratrol
Phase:
Study Start date:
February 02, 2024
Estimated Completion Date:
January 30, 2026

Study Description

We plan to enroll and screen 68 women, with an estimated 34 qualifying women will be randomly assigned to two groups: 1) the placebo group and 2) the resveratrol group. The resveratrol group will receive 500 mg resveratrol daily for 24 weeks, and placebo group will receive placebo pills. Both groups will receive 500 mg calcium plus 400 IU vitamin D daily.

Blood and urinary biomarkers of bone metabolism will be assessed at baseline and after 12 and 24 weeks intervention. Bone mineral density will be assessed using dual-energy X-ray absorptiometry at baseline and after 24 weeks.

Connect with a study center

  • University of Delaware

    Newark, Delaware 19716
    United States

    Site Not Available

Not the study for you?

Let us help you find the best match. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.